错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma

  • Benjamin Y. Lu,
  • Liliana E. Lucca,
  • Wesley Lewis,
  • Jiping Wang,
  • Catarina V. Nogueira,
  • Sebastian Heer,
  • Violeta Rayon-Estrada,
  • Pierre-Paul Axisa,
  • Sarah M. Reeves,
  • Nicholas C. Buitrago-Pocasangre,
  • Giang H. Pham,
  • Mina L. Kojima,
  • Wei Wei,
  • Lilach Aizenbud,
  • Antonietta Bacchiocchi,
  • Lin Zhang,
  • Joseph J. Walewski,
  • Veronica Chiang,
  • Kelly Olino,
  • James Clune,
  • Ruth Halaban,
  • Yuval Kluger,
  • Anthony J. Coyle,
  • Jan Kisielow,
  • Franz-Josef Obermair,
  • Harriet M. Kluger,
  • David A. Hafler

摘要

Effective anti-tumor immunity is driven by cytotoxic CD8+ T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify a subpopulation of CD8+ T cells that are tumor-antigen-specific and can be identified by KIR expression but paradoxically impair anti-tumor immunity in patients with melanoma. These tumor-antigen-specific KIR+CD8+ regulatory T cells target other tumor-antigen-specific CD8+ T cells, can be detected in both the tumor and the blood, have a conserved transcriptional program and are associated with a poor overall survival. These findings broaden our understanding of the transcriptional and functional heterogeneity of human CD8+ T cells and implicate KIR+CD8+ regulatory T cells as a cellular mediator of immune evasion in human cancer.